Cerebrolysin Moderate Evidence

What It Is

Cerebrolysin is a parenteral preparation of low-molecular-weight peptides and free amino acids produced by controlled enzymatic breakdown (pancreatic hydrolysis) of porcine brain tissue. Roughly 25% of the final product by weight consists of biologically active peptide fragments under 10 kilodaltons in molecular weight; the remaining 75% is free amino acids. It is manufactured by Ever Neuro Pharma in Austria and has been in continuous clinical use since the 1970s.

The product is formulated as a clear, sterile, slightly amber-colored aqueous solution supplied in 1 mL, 5 mL, 10 mL, 20 mL, and 30 mL ampoules at a concentration equivalent to 215.2 mg of peptide hydrolysate per 1 mL. It is administered exclusively as an intravenous infusion (diluted in saline or Ringer's solution) or intramuscular injection. The formulation is not stable for oral delivery — gastric proteases would degrade the peptide fraction within minutes of ingestion, and oral bioavailability has never been claimed.

Cerebrolysin is approved as a prescription pharmaceutical in approximately 44 countries — including Russia, China, Korea, Mexico, much of Eastern Europe (Romania, Poland, Ukraine, Hungary, Bulgaria), several Middle Eastern markets, and parts of Latin America and Southeast Asia. It is not approved by the U.S. Food and Drug Administration and is not centrally approved by the European Medicines Agency for the EU central market (national-authority approvals exist in some EU member states, but no centrally authorized EMA file). Approved indications across approving jurisdictions typically include ischemic stroke (acute and rehabilitation phase), traumatic brain injury, vascular dementia, Alzheimer's-type dementia, and pediatric perinatal brain injury.

Cerebrolysin's clinical research base is unusually large for a non-FDA-approved compound. PubMed indexes more than 200 published clinical trials, including multiple multicenter randomized placebo-controlled studies. The defining feature of this evidence base — and the source of the most consistent independent criticism — is that the overwhelming majority of trials have been sponsored, designed, or analyzed in collaboration with Ever Neuro Pharma. Independent reviewers, including the Cochrane Stroke Group, have noted this as a meaningful source of potential bias when interpreting effect sizes.

Mechanism of Action

Cerebrolysin is a multimodal compound — its biological activity reflects the combined effects of dozens of low-molecular-weight peptide fragments engaging multiple neurotrophic and neuroprotective pathways simultaneously. There is no single receptor target. The mechanistic literature, drawn primarily from preclinical models, attributes the following effects to the peptide fraction:

• Neurotrophic factor mimicry — The peptide fraction engages signaling pathways overlapping with nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), glial-derived neurotrophic factor (GDNF), and ciliary neurotrophic factor (CNTF). Cerebrolysin upregulates downstream effectors of these pathways including TrkA, TrkB, and PI3K-Akt, supporting neuronal survival, axon outgrowth, and synaptic remodeling. This neurotrophic mimicry is the central pharmacological claim of the compound (Brainin, 2018; Rejdak, 2023).
• Anti-apoptotic / anti-calpain activity — In ischemic and traumatic injury models, Cerebrolysin inhibits calpain activation, stabilizes cytoskeletal architecture (preserving alpha-II-spectrin and MAP-2), reduces caspase-3 cleavage, and limits delayed neuronal death in the penumbra surrounding a primary lesion.
• Anti-excitotoxicity — Modulates glutamate-mediated NMDA-receptor overactivation, reducing the calcium influx and oxidative cascade responsible for secondary neuronal injury after stroke and TBI.
• Microglial / neuroinflammation modulation — Reduces pro-inflammatory cytokine release (TNF-α, IL-1β, IL-6) from activated microglia in the post-injury brain while preserving microglial phagocytic clearance of debris. Bidirectional rather than blanket-suppressive — distinguishes it from steroid-class anti-inflammatories.
• Neurogenesis and synaptic plasticity — Promotes neuronal sprouting, increases synaptic density, and stimulates neurogenesis in the subventricular zone and hippocampal dentate gyrus in rodent stroke models. Modulates phosphatidylinositol-3-kinase (PI3K)/AKT, glycogen synthase kinase 3 beta (GSK3β), and Sonic hedgehog (Shh) signaling — pathways involved in adult neurogenesis and dendritic remodeling.
• Free radical / oxidative stress reduction — Reduces lipid peroxidation and reactive oxygen species (ROS) generation in cortical neurons exposed to ischemic insult; supports endogenous antioxidant capacity (glutathione peroxidase, superoxide dismutase).
• Amyloid metabolism modulation — In transgenic Alzheimer's mouse models, Cerebrolysin altered amyloid precursor protein (APP) maturation, reduced amyloid-β production, and improved behavioral performance — providing a mechanistic basis for the Alzheimer's clinical-trial program (Rockenstein et al., 2003).
• Mimics endogenous neuropeptide signaling — The peptide fraction is enriched in fragments resembling endogenous brain peptides; the precise identity of every active component has not been characterized, which is a source of regulatory complexity (Cerebrolysin is treated more like a biological extract than a defined-structure pharmaceutical).

What the Research Shows

Cerebrolysin's clinical evidence base spans four major indications — ischemic stroke, traumatic brain injury, vascular dementia, and Alzheimer's-type dementia — plus smaller pediatric and miscellaneous trial programs. The signal across this database is consistently positive on patient-reported and clinician-rated outcome scales but smaller and less consistent on rigorous mortality and disability endpoints when independently meta-analyzed.

• Ischemic stroke — CARS-1 and CARS-2 trials — The 2016 CARS-1 trial (Muresanu et al., Stroke; PMID 26564102) randomized 208 patients to 30 mL Cerebrolysin or placebo daily for 21 days during early post-stroke rehabilitation. The combined ARAT-day-90 endpoint indicated motor superiority for Cerebrolysin (Mann-Whitney 0.62, p<0.0001 in the pooled CARS-1/CARS-2 analysis), with NIHSS improvements at days 14 and 21 and a number-needed-to-treat (NNT) of approximately 7.1 for clinically relevant change.
• Ischemic stroke — CASTA Asian trial — The 2012 CASTA trial (Heiss, Brainin, Bornstein, Tuomilehto, Hong et al., Stroke; PMID 22282884) was the largest acute-phase Cerebrolysin stroke trial, randomizing patients within 12 hours of symptom onset across multiple Asian countries. The confirmatory endpoint was neutral, but a pre-specified subgroup (severe NIHSS >12) showed a favorable outcome trend — a result that has shaped the field's framing of Cerebrolysin as a higher-value intervention in more severe strokes.
• Stroke meta-analysis — The 2018 Bornstein meta-analysis of nine RCTs (PMID 29248999) combined 1,879 patients and reported NIHSS-30 superiority for Cerebrolysin (Mann-Whitney 0.60, p<0.0001), with combined NNT of 7.7 for clinically relevant change.
• Stroke Cochrane review — The 2023 update by Ziganshina et al. (Cochrane Database Syst Rev; PMID 37818733) judged moderate-certainty evidence indicating Cerebrolysin probably has no beneficial effect on preventing all-cause mortality after acute ischemic stroke and probably no beneficial effect on functional independence as measured by modified Rankin Scale. The Cochrane verdict is the most rigorously methodologically conservative independent assessment available; it differs from the sponsor-pooled meta-analyses primarily by emphasizing methodological quality and risk-of-bias judgment over effect-size pooling.
• Traumatic brain injury — CAPTAIN I and II — The CAPTAIN I trial (Poon et al., Neurol Sci 2019; PMID 31494820) and CAPTAIN II trial (Muresanu et al., Neurol Sci 2020; PMID 31897941) evaluated Cerebrolysin in 46 and 142 patients respectively after moderate-to-severe TBI. Both used a multidimensional 13-scale outcome ensemble and reported "small-to-medium" effect sizes favoring Cerebrolysin, with statistical significance at day 90 for the multivariate ensemble (CAPTAIN II: MW 0.59, p=0.0119). The 2021 prospective meta-analysis of the two trials (PMID 33620612) confirmed small-to-medium effect at days 30 and 90.
• Vascular dementia — Cochrane review — The 2019 Cochrane review by Cui et al. (PMID 31710397) included six RCTs (597 participants) and reported beneficial effects on cognitive function (MMSE WMD ~1.10) and global outcome but rated the evidence as low-certainty due to imprecision, sponsorship, and heterogeneity. Conclusion: insufficient evidence to recommend Cerebrolysin as routine treatment for vascular dementia, although a clinically meaningful signal exists.
• Alzheimer's disease meta-analysis — The 2015 meta-analysis (Gauthier et al., Dement Geriatr Cogn Disord; PMID 25832905) of randomized double-blind placebo-controlled trials reported Cerebrolysin superiority on cognitive function at 4 weeks (SMD −0.40; p=0.0031), global clinical change (OR 3.32 at 4 weeks; OR 4.98 at 6 months), and the combined "global benefit" endpoint at both timepoints. Effect sizes are modest but consistent.
• Subarachnoid hemorrhage pilot — Woo et al., BMC Neurol 2020 (PMID 33143640) — a randomized placebo-controlled pilot in aneurysmal SAH patients found acceptable safety; efficacy signals were exploratory and require confirmatory trials.
• Aphasia adjunct — Jianu et al., J Med Life 2010 (PMID 20945821) — Cerebrolysin as adjunct in Broca's aphasia after left middle cerebral artery stroke, reporting language-recovery improvement on standardized aphasia scales.
• Pediatric perinatal brain injury — Hassanein et al., J Clin Neurol 2016 (PMID 26365023) — randomized controlled trial in infants with communication defects from severe perinatal brain insult, reporting language-development improvement on Cerebrolysin compared with controls.

Human Data

Unlike most peptides on this site, Cerebrolysin's primary evidence base is human data. More than 200 clinical trials have been published across stroke, TBI, dementia, and pediatric indications. Selected pivotal and confirmatory studies:

• CARS-1 (PMID 26564102) — 208 patients; 30 mL Cerebrolysin daily for 21 days during early post-stroke rehabilitation. Primary endpoint: ARAT day 90 motor function. Pooled CARS-1/2 analysis: motor superiority Mann-Whitney 0.62, p<0.0001.
• CASTA (PMID 22282884) — 1,070 patients across Asian sites; 30 mL Cerebrolysin daily for 10 days within 12 hours of acute ischemic stroke onset. Confirmatory endpoint neutral; pre-specified severe-stroke subgroup (NIHSS >12) showed a favorable outcome trend.
• Bornstein 2018 nine-trial meta-analysis (PMID 29248999) — 1,879 patients pooled across nine acute and early-recovery stroke RCTs. NIHSS day 30 Mann-Whitney 0.60, p<0.0001; combined NNT 7.7 for clinically relevant change.
• Gharagozli 2017 (PMID 29075343) — Iranian multicenter RCT, 30 mL Cerebrolysin daily for 7 days then 10 mL daily through day 30. Cerebrolysin superior on NIHSS day 30 (MW 0.66; p=0.005), modified Rankin Scale (MW 0.65; p=0.010), and Clinical Global Impression (MW 0.70; p=0.006).
• CAPTAIN I (PMID 31494820) — 46 patients with moderate-severe TBI; multidimensional outcome ensemble. Stand-alone significance on Stroop, Color Trails 1 and 2; ITT primary multivariate ensemble missed significance at p<0.1.
• CAPTAIN II (PMID 31897941) — 142 patients with moderate-severe TBI; multidimensional 13-scale ensemble. Statistically significant at day 90 (MW 0.59, p=0.0119).
• CAPTAIN meta-analysis (PMID 33620612) — Combined CAPTAIN I + II (185 patients). Small-to-medium effect favoring Cerebrolysin at days 30 and 90.
• Vascular dementia Cochrane (PMID 31710397) — Six RCTs, 597 participants. Beneficial effect on cognitive function (MMSE WMD ~1.10) and global outcome; rated low-certainty.
• Mild-to-moderate Alzheimer's meta-analysis (PMID 25832905) — Cognitive function SMD −0.40 at 4 weeks; global clinical change OR 3.32 at 4 weeks, OR 4.98 at 6 months.
• SAH pilot (PMID 33143640) — Randomized placebo-controlled pilot in aneurysmal subarachnoid hemorrhage; acceptable safety, exploratory efficacy.

The 2023 Cochrane stroke review (PMID 37818733) is the single most rigorous independent appraisal: moderate-certainty evidence that Cerebrolysin probably has no beneficial effect on preventing all-cause death and probably has no beneficial effect on functional independence in acute ischemic stroke. The discrepancy between sponsor-pooled meta-analyses (positive small-to-medium effect on rating scales) and Cochrane mortality conclusions (no benefit) reflects different methodological priorities, not a contradiction in the underlying data.

Dosing from the Literature

Cerebrolysin is a clinic-administered parenteral preparation. The following dosing summarizes the regimens used in the major trials. It is not a self-administration guide, and Cerebrolysin is not legally available from U.S. compounding pharmacies.

Reconstitution & Storage

Cerebrolysin is supplied as a sterile aqueous solution (no reconstitution required) in single-use ampoules of 1, 5, 10, 20, and 30 mL. Standard concentration is approximately 215.2 mg of peptide hydrolysate per 1 mL.

• Compatibility — Compatible with 0.9% sodium chloride, 5% dextrose, and Ringer's solution. Do not mix with amino acid solutions, lipid emulsions, or alkaline solutions (pH instability). Do not mix with vitamin or balanced electrolyte solutions in the same line.
• Infusion rate — Slow IV infusion over 30–60 minutes is typical for 10–30 mL doses; faster bolus has been associated with infusion-rate-related adverse events (hyperventilation, dizziness, palpitations).
• Storage — Sealed ampoules stable at room temperature (below 25°C) protected from light. Do not freeze. Once opened, use immediately (single-use only — discard residual).
• Inspection — Solution should be clear and slightly amber. Discard if cloudy, discolored beyond pale amber, or showing visible particulate.

→ Use the Kalios Dosing Calculator for parenteral conversions

Side Effects & Risks

Cerebrolysin's safety profile is among the most extensively characterized in this category, drawn from decades of clinical use in 44+ countries plus controlled trial data:

• Most commonly reported (≥1% in clinical trials) — Mild infusion-related reactions including warmth or flushing during infusion, transient sweating, dizziness, headache, mild nausea. These are typically dose- and rate-related and resolve with slower infusion or dose reduction.
• Infusion-rate-related adverse events — Rapid IV bolus has been associated with hyperventilation, palpitations, brief blood-pressure swings, and feelings of agitation. Slow infusion over 30–60 minutes prevents most of these reactions.
• Hypersensitivity / allergic reactions — Rare (<0.1%) hypersensitivity reactions including rash, urticaria, and isolated anaphylactoid reactions have been reported in pharmacovigilance data. As a porcine-derived biological extract, sensitization is biologically plausible. Patients with prior allergic reactions to porcine proteins should not receive Cerebrolysin.
• Injection-site reactions (IM) — Local pain, erythema, and induration with intramuscular administration. Typically self-limiting.
• Seizure risk — Cerebrolysin is contraindicated by the manufacturer in patients with status epilepticus and grand mal epilepsy; the neurotrophic / neuroexcitatory profile creates theoretical risk of lowering seizure threshold. Reports in patients without prior epilepsy are rare.
• Severe renal impairment — Manufacturer contraindication includes severe renal failure due to lack of renal-impaired pharmacokinetic data; clinical experience in renal-failure patients is limited.
• Pregnancy and lactation — Insufficient human data; manufacturer advises use only when benefit clearly outweighs risk. Avoid where possible.
• Pediatric use — Used routinely in children in approving jurisdictions for perinatal brain injury and developmental indications; dose is weight-adjusted (0.1–0.2 mL/kg/day IM for typical pediatric courses).
• Long-term safety — Decades of post-marketing pharmacovigilance in approving countries have not surfaced novel long-term safety signals. Cumulative dose-response data is limited; most clinical experience is with cyclical short-course administration (10–30 days repeated periodically) rather than continuous chronic dosing.
• Drug interactions — No significant interactions reported with antiplatelet, antihypertensive, statin, or standard anticonvulsant medications. Caution advised when combining with MAO inhibitors due to theoretical neurotransmitter-modulation overlap.
• Theoretical concerns — As a brain-derived biological from porcine source, prion safety has been evaluated; manufacturing processes include validated steps for prion clearance, and decades of clinical use have not surfaced TSE/CJD-related signals. Independent verification of manufacturing controls is the practical floor for confidence.

Bloodwork & Monitoring

Cerebrolysin is administered exclusively in clinical settings in approving jurisdictions; standard monitoring follows the indication's clinical practice guidelines. For research-context awareness:

• Baseline CMP and CBC — Standard pre-treatment chemistry and complete blood count before starting any parenteral course. Confirm renal function (eGFR) given manufacturer contraindication for severe renal failure.
• Hepatic function — AST/ALT/total bilirubin baseline. Cerebrolysin does not have known hepatotoxic signal but baseline is standard.
• Allergy / IgE history — Document prior reactions to porcine proteins, prior parenteral biological reactions, atopic history before first administration.
• Vital signs during infusion — Blood pressure, heart rate, respiratory rate at baseline and at 15-minute intervals during the first infusion. Infusion-rate-related reactions are the most common safety event.
• Indication-specific monitoring — For stroke: NIHSS at baseline, day 7, day 21, day 90. For TBI: GCS at baseline; multidimensional neuropsychological battery at days 30 and 90 (mirroring CAPTAIN). For dementia: ADAS-cog and CIBIC+ baseline and at end-of-cycle.
• Imaging — Indication-driven (CT/MRI for stroke and TBI baseline; imaging follow-up per local protocol).
• Seizure surveillance — In patients with prior epilepsy or seizure-risk neurology, EEG monitoring at clinician discretion during initial courses.

Commonly Stacked With

In approving jurisdictions, Cerebrolysin is most often used as an adjunct to standard-of-care for the indication in question rather than as monotherapy.

→ Check compound compatibility in the Stack Builder

Regulatory Status

Related Compounds

Neurotrophic and nootropic peptides that sit next to Cerebrolysin in the brain-recovery toolkit.

Next Steps

Key References

1. Muresanu DF, Heiss WD, Hoemberg V, Bajenaru O, Popescu CD, Vester JC, Rahlfs VW, Doppler E, Meier D, Moessler H, Guekht A. Cerebrolysin and Recovery After Stroke (CARS): A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial. Stroke. 2016;47(1):151-159. PMID: 26564102.
2. Heiss WD, Brainin M, Bornstein NM, Tuomilehto J, Hong Z; Cerebrolysin Acute Stroke Treatment in Asia (CASTA) Investigators. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. Stroke. 2012;43(3):630-636. PMID: 22282884.
3. Bornstein NM, Guekht A, Vester J, Heiss WD, Gusev E, Hömberg V, Rahlfs VW, Bajenaru O, Popescu BO, Muresanu D. Safety and efficacy of Cerebrolysin in early post-stroke recovery: a meta-analysis of nine randomized clinical trials. Neurol Sci. 2018;39(4):629-640. PMID: 29248999.
4. Gharagozli K, Harandi AA, Houshmand S, Akbari N, Muresanu DF, Vester J, Winter S, Moessler H. Efficacy and safety of Cerebrolysin treatment in early recovery after acute ischemic stroke: a randomized, placebo-controlled, double-blinded, multicenter clinical trial. J Med Life. 2017;10(3):153-160. PMID: 29075343.
5. Ziganshina LE, Abakumova T, Nurkhametova D, Ivanchenko K. Cerebrolysin for acute ischaemic stroke. Cochrane Database Syst Rev. 2023;10(10):CD007026. PMID: 37818733. (The 2023 Cochrane independent appraisal — the most methodologically conservative review available; concluded probable no effect on all-cause mortality or functional independence.)
6. Cui S, Chen N, Yang M, Guo J, Zhou M, Zhu C, He L. Cerebrolysin for vascular dementia. Cochrane Database Syst Rev. 2019;(11):CD008900. PMID: 31710397. (Six-RCT review; beneficial cognitive and global signal; rated low-certainty.)
7. Chen N, Yang M, Guo J, Zhou M, Zhu C, He L. Cerebrolysin for vascular dementia. Cochrane Database Syst Rev. 2013;(1):CD008900. PMID: 23440834. (Original 2013 Cochrane vascular-dementia review.)
8. Gauthier S, Proaño JV, Jia J, Froelich L, Vester JC, Doppler E. Cerebrolysin in mild-to-moderate Alzheimer's disease: a meta-analysis of randomized controlled clinical trials. Dement Geriatr Cogn Disord. 2015;39(5-6):332-347. PMID: 25832905.
9. Poon W, Vos P, Muresanu D, Vester J, von Wild K, Hömberg V, et al. Safety and efficacy of Cerebrolysin in acute brain injury and neurorecovery: CAPTAIN I — a randomized, placebo-controlled, double-blind, Asian-Pacific trial. Neurol Sci. 2020;41(2):281-293. PMID: 31494820.
10. Muresanu DF, Florian S, Hömberg V, Matula C, von Steinbüchel N, Vos PE, von Wild K, Birle C, Muresanu I, Slavoaca D, Rosu OV, Strilciuc S, Vester J. Efficacy and safety of cerebrolysin in neurorecovery after moderate-severe traumatic brain injury: results from the CAPTAIN II trial. Neurol Sci. 2020;41(5):1171-1181. PMID: 31897941.
11. Vester JC, Buzoianu AD, Florian SI, Hömberg V, Kim SH, Lee TMC, Matula C, Poon WS, von Steinbüchel N, Strilciuc S, von Wild K, Muresanu D. Cerebrolysin after moderate to severe traumatic brain injury: prospective meta-analysis of the CAPTAIN trial series. Neurol Sci. 2021;42(2):589-598. PMID: 33620612.
12. Brainin M. Cerebrolysin: a multi-target drug for recovery after stroke. Expert Rev Neurother. 2018;18(8):681-687. PMID: 30004268.
13. Rejdak K, Sienkiewicz-Jarosz H, Bienkowski P, Alvarez A. Modulation of neurotrophic factors in the treatment of dementia, stroke and TBI: Effects of Cerebrolysin. Med Res Rev. 2023;43(5):1668-1700. PMID: 37052231.
14. Woo PYM, Ho JWK, Ko NMW, Li RPT, Jian L, Chu ACH, Kwan MCL, Chan Y, Wong AKS, Wong HT, Chan KY, Kwok JCK. Randomized, placebo-controlled, double-blind, pilot trial to investigate safety and efficacy of Cerebrolysin in patients with aneurysmal subarachnoid hemorrhage. BMC Neurol. 2020;20(1):401. PMID: 33143640.
15. Hassanein SM, Deifalla SM, El-Houssinie M, Mokbel SA. Safety and Efficacy of Cerebrolysin in Infants with Communication Defects due to Severe Perinatal Brain Insult: A Randomized Controlled Clinical Trial. J Clin Neurol. 2016;12(1):79-84. PMID: 26365023.
16. Jianu DC, Muresanu DF, Bajenaru O, Popescu BO, Deme SM, Moessler H, Meinzingen SZ, Petrica L. Cerebrolysin adjuvant treatment in Broca's aphasics following first acute ischemic stroke of the left middle cerebral artery. J Med Life. 2010;3(3):297-307. PMID: 20945821.
17. Heiss WD, Brainin M, Bornstein NM, Tuomilehto J, Hong Z. A double-blind, placebo-controlled, randomized trial to evaluate the safety and efficacy of Cerebrolysin in patients with acute ischaemic stroke in Asia — CASTA. Int J Stroke. 2010;5(4):310-313. PMID: 19765131.
18. Ladurner G, Kalvach P, Moessler H; Cerebrolysin Study Group. Neuroprotective treatment with cerebrolysin in patients with acute stroke: a randomised controlled trial. J Neural Transm (Vienna). 2005;112(3):415-428. PMID: 15583955.
19. Onose G, Mureşanu DF, Ciurea AV, Daia Chendreanu C, et al. Neuroprotective and consequent neurorehabilitative clinical outcomes in patients treated with the pleiotropic drug cerebrolysin. J Med Life. 2009;2(4):350-360. PMID: 20108749.
20. Rockenstein E, Adame A, Mante M, Moessler H, Windisch M, Masliah E. The neuroprotective effects of Cerebrolysin in a transgenic model of Alzheimer's disease are associated with improved behavioral performance. J Neural Transm (Vienna). 2003;110(11):1313-1327. PMID: 14628194.